<DOC>
	<DOCNO>NCT03002376</DOCNO>
	<brief_summary>This study conduct compare relationship patient response treatment change tumor environment .</brief_summary>
	<brief_title>An Exploratory Tumor Biopsy-driven Study Understand Relationship Between Biomarkers Clinical Response Melanoma Patients Receiving REGN2810 ( Anti-PD-1 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis stage III ( unresectable ) stage IV melanoma least 1 lesion measurable RECIST 1.1 criterion accessible biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Adequate hepatic function Adequate renal function Adequate bone marrow function Willing able comply clinic visit studyrelated procedure Provide sign informed consent Able understand complete studyrelated questionnaire Anticipated life expectancy &gt; 12 week Ongoing recent ( within 5 year ) evidence significant autoimmune disease require treatment systemic immunosuppressive treatment , may suggest risk immunerelated adverse event ( irAEs ) . Prior treatment agent block program death1/ program deathligand 1 ( PD1/PDL1 pathway ) Prior treatment immune modulate anticancer agent , except remote treatment ( &gt; 6 month ) adjuvant set . Untreated brain metastasis ( es ) may consider active . Immunosuppressive corticosteroid dos ( &gt; 10 mg prednisone daily equivalent ) within 4 week prior first dose REGN2810 Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>